TITLE

Leflunomide: A Review of its Use in Active Rheumatoid Arthritis

AUTHOR(S)
Prakash, A.; Jarvis, B.
PUB. DATE
December 1999
SOURCE
Drugs;Dec1999, Vol. 58 Issue 6, p1137
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A77 1726, the active metabolite of leflunomide, is an immunomodulator which inhibits cell proliferation in activated lymphocytes in patients with active rheumatoid arthritis. Because A77 1726 has a long half-life (≈2 weeks), treatment with oral leflunomide is initiated with a loading dose of 100mg once daily for 3 days and continued with 20mg once daily. Results of large randomised, double-blind, multicentre trials of up to 24 months' duration have shown that leflunomide is significantly superior to placebo and at least as effective as sulfasalazine in improving primary outcome measures, such as tender joint counts, swollen joint counts and physicians' and patients' global assessment, in adult patients with active rheumatoid arthritis. Whereas improvement in all primary outcome measures with leflunomide was similar to or significantly less than that with methotrexate after 12 months, the efficacy of both agents was similar after 24 months. The therapeutic effect of leflunomide appears earlier (at 4 weeks) than that of sulfasalazine or methotrexate, and reduction from baseline values in functional disability was significantly greater with leflunomide than with sulfasalazine, methotrexate or placebo at end-point. Leflunomide was at least as effective as sulfasalazine or methotrexate in delaying the rate of radiological progression of disease. The most common adverse events reported in patients receiving leflunomide in randomised double-blind, placebo-controlled trials were diarrhoea (27%), respiratory infections (21%), nausea (13%), headache (13%), rash (12%), increased serum hepatic aminotransferases (10%), dyspepsia (10%) and alopecia (9%). Leflunomide was as well tolerated as sulfasalazine or methotrexate in clinical trials. Monitoring of serum hepatic enzyme levels is recommended in patients receiving leflunomide. The drug is not recommended in female patients who are or may become pregnant. Drug treatment should be discontinued, and hastened drug elimination procedure should be considered, in male patients wishing to father a child. 16 potential cases of pancytopenia and 9 cases of serious skin reactions have been associated with the use of leflunomide in 76 000 patients to date. Conclusions: Leflunomide is a disease-modifying antirheumatic drug which reduces the signs and symptoms of inflammatory arthritis and delays the radiological progression of disease in adult patients with active rheumatoid arthritis. The drug appears to be as effective and as well tolerated as sulfasalazine or methotrexate, and represents a suitable alternative to these agents in adult patients with active rheumatoid arthritis. Benefits with leflunomide are evident within 4 weeks and efficacy is maintained for durations of up to 24 months.
ACCESSION #
9592922

 

Related Articles

  • New immunomodulator relieves eczema. Karpa, Kelly Dowhower // Drug Topics;1/21/2002, Vol. 146 Issue 2, p19 

    Introduces the Pimecrolimus drug, an immunomodulator developed by Novartis for treating eczema. Effect of the drug on T cells; Advantages of the drug; Results of the clinical trials made on the drug. INSET: TIPS TO REMEMBER.

  • Lenograstim.  // Reactions Weekly;Feb2014, Vol. 1489 Issue 1, p23 

    The article presents two case studies of patients diagnosed with pulmonary adverse events developed while receiving lenograstim.

  • Ciclosporin.  // Reactions Weekly;Feb2014, Vol. 1489 Issue 1, p13 

    The article presents a case study of a 4-year-old boy diagnosed with anaphylaxis developed while receiving ciclosporin for aplastic anaemia.

  • Improving Vaccine Performance with Adjuvants. Vogel, Frederick R. // Clinical Infectious Diseases;6/1/2000 Supplement 3, Vol. 30, pS266 

    Analyzes the potential advantages of incorporating adjuvants into vaccine formulations. Types of immunologic adjuvants; Promotion of cell-mediated responses; Decrease in the frequency of immunization required to provide protective immunity; Risk of inducing local adverse reactions.

  • Biologic response modifiers. Hoi Soo Yoon; Yong Sung Choi; Eun Hye Lee // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;Feb2013, Vol. 56 Issue 2, p135 

    Biotherapy, often called biological therapy or immunotherapy, aims at supporting and helping in the treatment of human disease without chemical drugs and invasive therapies, by restoring the natural immune system. It is also used to reduce certain side effects that may be caused by some...

  • Treatment Improves TBI Symptoms Years After Injury.  // Journal of Psychosocial Nursing & Mental Health Services;Jan2013, Vol. 51 Issue 1, p47 

    No abstract available.

  • First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis. Johnston, Jessica // Drugs;2012, Vol. 72 Issue 9, p1195 

    Paediatric multiple sclerosis (MS) is defined as the onset of MS before the age of 18 years. Immunomodulatory disease-modifying therapies (i.e. the interferons [IFNs] and glatiramer acetate) are considered first-line treatments in adult patients with MS, but they are largely understudied in the...

  • Vaxart Series A For Vaccine Research.  // Bioworld Week;11/19/2007, Vol. 15 Issue 47, p5 

    The article reports on the $3.3 million raised by Vaxart Inc. to finance its preclinical studies on a vaccine platform in the U.S. It relates that the vaccine platform is designed to be administered orally and can deliver substitutable target antigens accompanied by an adjuvant. In addition, the...

  • Miscellaneous.  // Current Medical Literature: Rheumatology;2011, Vol. 30 Issue 4, p142 

    The article presents a study which aimed to determine the treatment of influenza in immuno-compromised patients in preventing the development of respiratory complications. It also discusses the role of oil-in-water squalene-based adjuvanted influenza vaccines/H1N1 vaccines for patients with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics